Download PDF
Thromb Haemost 1978; 40(02): 428-438
DOI: 10.1055/s-0038-1648677
Original Article
Schattauer GmbH Stuttgart

In Vitro and In Vivo Effects of Adrenaline and Phentolamine on Platelet Function

Oreste Ponari
The Centro per le Malattie Emostatiche, Ospedali Riuniti di Parma, Parma, Italy
,
Emilio Civardi
The Centro per le Malattie Emostatiche, Ospedali Riuniti di Parma, Parma, Italy
,
Alessandro Megha
The Centro per le Malattie Emostatiche, Ospedali Riuniti di Parma, Parma, Italy
,
Mario Pini
The Centro per le Malattie Emostatiche, Ospedali Riuniti di Parma, Parma, Italy
,
Raffaele Poti’
The Centro per le Malattie Emostatiche, Ospedali Riuniti di Parma, Parma, Italy
,
Anton Giulio Dettori
The Centro per le Malattie Emostatiche, Ospedali Riuniti di Parma, Parma, Italy
› Author Affiliations
Further Information

Publication History

Received 30 March 1977

Accepted 25 March 1978

Publication Date:
12 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

In vitro and in vivo effects of adrenaline (ADR) on platelet aggregation, on platelet factor 3 (PF3) availability and on platelet factor 4 (PF4) release were studied in man. Inhibitory action of an alpha-blocker, phentolamine (PHEN) was investigated in the same conditions.

The threshold concentration (TC) of ADR inducing the typical two-phase response in aggregation tests when added to platelet-rich plasma (PRP) varied in different pools of plasma, but always induced an evident PF4 release and increased PF3 availability. A further increase in both parameters was obtained with higher concentrations but without any significant dose/response correlation.

Adding PHEN alone to PRP did not induce platelet aggregation or modify PF4 release induced by stirring, but it reduced PF3 availability. On the other hand, PHEN prevented the effects of ADR in different platelet tests, at appropriate concentrations.

Intravenous infusion of ADR lowered the TC, and increased PF3 availability and PF4 release. In vivo administration of PHEN, in contrast, increased TC and reduced PF3 availability, while PF4 remained unchanged.

 

  • References

  • 1 Brecher G, Cronkite EP. 1950; Morphology and enumeration of human blood platelets. Journal of Applied Physiology 3: 365
    CrossrefPubMedGoogle Scholar
  • 2 Bygdeman S, Johnsen Ø. 1969; Studies on the effect of adrenergic blocking drugs on catecholamine-induced platelet aggregation and uptake of noradrenaline and 5-hydroxytryptamine. Acta Physiologica Scandinavia 75: 129
    CrossrefPubMedGoogle Scholar
  • 3 De Gaetano G, Vermylen J, Verstraete M. 1972. Platelet factor 3. Properties and clinical significance In: Mannucci PM, Gorini S. (Eds) Platelet function and thrombosis. A review of methods Plenum Press; New York - London: p 159
    Google Scholar
  • 4 Donati MB, Palester-Chzebowczyk M, Degaetano G, Vermylen J. 1972. Platelet factor 4. Properties and clinical significance In: Mannucci PM, Gorini S. (Eds): Platelet function and thrombosis. A review of methods Plenum Press; New York - London: p 173
    Google Scholar
  • 5 Fiorentini P. Adesività e aggregazione piastrinica dopo carico di adrenalina nel normale e nell’iperteso. Proceedings of the 1st Meeting of the “Società Italiana per lo Studio dell’Emostasi e della Trombosi”.Parma 29.11.1971
    PubMedGoogle Scholar
  • 6 Haft JL, Gershengorn K, Kranz PD, Oestreicher R. 1972; a Protection against epinephrine - induced myocardial necrosis by drugs that inhibit platelet aggregation. American Journal of Cardiology 30: 838
    CrossrefPubMedGoogle Scholar
  • 7 Haft JL, Kranz PD, Albert FJ, FANI K. 1972; b Intravascular platelet aggregation in the heart induced by norepinephrine. Microscopic studies Circulation 46: 698
    CrossrefPubMedGoogle Scholar
  • 8 Harada K, Zucker MB. 1971; Simultaneous development of platelet factor 4 activity and release of 14C-serotonin. Thrombosis et Diathesis haemorrhagica 25: 41
    PubMedGoogle Scholar
  • 9 Hardisty RM, Hutton RA, Montgomery D, Rickard S, Trebilcock H. 1970; Secondary platelet aggregation: a quantitative study. British Journal of Haematology 19: 307
    CrossrefPubMedGoogle Scholar
  • 10 Kubisz P, Levy-Toledano S, Cronberg S, Pinkhas J, Caen J. 1970; Effect of phentolamine, an alpha-receptor blocking agent, on epinephrine, ADP and collagen-induced platelet factor 4 release and platelet aggregation. Revue Européenne d’Etudes Cliniques et Biologiques 15: 429
    PubMedGoogle Scholar
  • 11 Libre EP, Cowan DH, Watkins Jr SP, Shulman NR. 1968; Relationship between spleen, platelets and factor Vili levels. Blood 31: 358
    PubMedGoogle Scholar
  • 12 LüScher EF, Kaser-Glanzmann R. 1975; Platelet heparinneutralizing factor (platelet factor 4). Thrombosis et Diathesis haemorrhagica 33: 66
    PubMedGoogle Scholar
  • 13 Macmillan DC. 1966; Secundary clumping effect in human citrated platelet-rich plasma produced by adenosine diphosphate and adrenaline. Nature (London) 211: 140
    CrossrefPubMedGoogle Scholar
  • 14 Mcclure PD, Ingram GI C, Vaughan Jones R. 1965; Platelet changes after adrenaline infusions with and without adrenaline blockers. Thrombosis et Diathesis haemorrhagica 13: 136
    PubMedGoogle Scholar
  • 15 Mills DC B, Roberts CC K. 1967; Effects of adrenaline on human blood platelets. Journal of Physiology 193: 443
    CrossrefPubMedGoogle Scholar
  • 16 Mitchell JR A, Sharp AA. 1964; Platelet-clumping in vitro. British Journal of Haematology 10: 78
    CrossrefPubMedGoogle Scholar
  • 17 Niewiarowski S, Lipinski B, Farbiszewski R, Poplawski A. 1968; The release of platelet factor 4 during platelet aggregation and the possible significance of this reaction in hemostasis. Experientia (Basel) 24: 343
    CrossrefPubMedGoogle Scholar
  • 18 O’Brien JR. 1963; Some effects of adrenaline and antiadrenaline compounds on platelets “in vitro” and “in vivo”. Nature (London) 200: 763
    CrossrefPubMedGoogle Scholar
  • 19 O’Brien JR. 1964; Variability in the aggregation of human platelets by adrenaline. Nature (London) 202: 1188
    CrossrefPubMedGoogle Scholar
  • 20 O’Brien JR, Etherington MD. 1976; An inverse relation between platelet factor 4 in the platelet and in the plasma. Thrombosis and Haemostasis 36: 649
    Article in Thieme ConnectPubMedGoogle Scholar
  • 21 Ozge AH, Mustard JF, Hegardt B, Rowsell HC, Downie HG. 1963; The effect of adrenaline on blood coagulation, platelet economy and thrombus formation. Canadian Journal of Medical Association 88: 265
    PubMedGoogle Scholar
  • 22 Ponari O, Cattabiani G, Mastandrea R, et Dettori AG. 1965; Les rapports entre le systéme nerveux et les phénomènes de coagulation et de fibrinolyse. Revue critique et contribution personnelle Hémostase 5: 379
    PubMedGoogle Scholar
  • 23 Robison GA, Arnold A, Hartmann RC. 1969; Divergent effects of epinephrine and prostaglandin E1 on the level of cyclic AMP in human blood platelets. Pharmacological Research Communications 1: 325
    CrossrefPubMedGoogle Scholar
  • 24 Rowsell HC, Hegardt B, Downie HG, Mustard JF, Murphy EA. 1966; Adrenaline and experimental thrombosis. British Journal of Haematology 12: 66
    CrossrefPubMedGoogle Scholar
  • 25 Rysanek K, Svehla C, Spankova H, Mlejnkova M. 1968 Comparison of the effect of various sympathicolytics on thrombocyte aggregation. Journal of Pharmacy and Pharmacology. 20.
    PubMedGoogle Scholar
  • 26 Schwartz CJ, Ardlie NG. 1967; Catecholamines and platelet aggregation. Circulation Research 21 Suppl (Suppl. 03) 187
    PubMedGoogle Scholar
  • 27 Spaet TH, Cintron J. 1965; Studies on platelet factor 3 availability. British Journal of Haematology 11: 269
    CrossrefPubMedGoogle Scholar
  • 28 Yamazaki H, Sano T, Odakura T, Takeuchi K, Matsumura T, Hosaki S, Shimamoto T. 1971; Appearance of thrombogenic tendency induced by adrenaline and its prevention by beta- adrenergic blocking agents, Nialamide and Pyridinolcarbamate. Thrombosis et Diathesis haemorrhagica 26: 251
    PubMedGoogle Scholar
  • 29 Youssef A, Barkhan P. 1968; Release of platelet factor 4 by adenosine diphosphate and other platelet-aggregating agents. British Medical Journal 1: 746
    CrossrefPubMedGoogle Scholar
  • 30 Weiss HJ, Willis AL, Kuhn D, Brand H. 1976; Prostaglandin E2 potentiation of platelet aggregation induced by LASS endoperoxide: absent in storage pool disease, normal after Aspirin ingestion. British Journal of Haematoloy 32: 257
    PubMedGoogle Scholar
  • 31 Willis AL, Vane FM, Kuhn DC, Scott CG, Petrin M. 1974; An endoperoxide aggregator (LASS) formed in platelets in response to thrombotic stimuli. Prostaglandins 8: 453
    CrossrefPubMedGoogle Scholar